Xceleron makes key appointments

Hires board member and senior director of operations

Xceleron, a UK specialist in accelerating drug development using ultra-sensitive bioanalytical analyses, has appointed Dr David Roblin to its board of directors in a non-executive capacity.

In addition, the York-based firm says Dr Stuart Best has joined the company as senior director of operations.

Dr Roblin joins the firm from Pfizer global r&d where he was most recently senior vice president r&d, research head and site director. His experience crosses therapeutic areas within the spectrum of small and large molecule r&d.

Dr Best was previously head of bioanalysis at Merck, Scotland. His career has been distinguished by his leadership in applying progressively sophisticated analytical technologies to this expanding and complex area of chemistry. Prior to Merck, Dr Best developed his reputation as an authority in the use of mass spectrometry in bioanalysis at Charles River (Inveresk).

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility

The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development

VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development

The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Research & Development

Brainomix and Boehringer Ingelheim continue partnership in pulmonary fibrosis

The pair will advance their strategic partnership to the next phase of clinical trials for Brainomix's e-Lung after strong initial results demonstrated its potential to enable earlier diagnosis of progressive pulmonary fibrosis
Subscribe now